Related Experiment Videos
A transgenic mouse model of sickle cell disorder
D R Greaves1, P Fraser, M A Vidal
1Laboratory of Gene Structure and Expression, National Institute for Medical Research, The Ridgeway, Mill Hill, London, UK.
Nature
|January 11, 1990
Summary
Scientists developed a transgenic mouse model for sickle cell anemia. This model exhibits red blood cell sickling, crucial for studying the disease and developing new treatments.
Area of Science:
- Genetics
- Hematology
- Animal Models
Background:
- Sickle cell anemia is caused by a specific mutation in the beta-globin gene (beta s).
- The resulting mutant hemoglobin (HbS) polymerizes under deoxygenation, deforming red blood cells and causing severe complications.
- Despite understanding the molecular basis, effective treatments for sickle cell anemia remain elusive.
Purpose of the Study:
- To create a viable animal model for sickle cell anemia.
- To facilitate in-depth analysis of erythrocyte sickling mechanisms and disease pathophysiology.
- To enable the development of novel therapeutic strategies for sickle cell anemia.
Main Methods:
- Utilized human beta-globin locus control region sequences.
- Incorporated human alpha- and beta s-globin genes.
- Generated three transgenic mouse lines expressing varying levels of HbS (10-80% of total hemoglobin).
Main Results:
- Transgenic mice displayed red blood cell sickling upon deoxygenation, mirroring human sickle cell anemia.
- Mice with higher HbS levels exhibited irreversibly sickled cells in peripheral blood, similar to homozygous patients.
- The model successfully recapitulates key features of sickle cell disease.
Conclusions:
- The developed transgenic mouse is a valuable model for sickle cell anemia research.
- This model allows for the study of in vivo sickling and disease progression.
- It provides a platform for testing and advancing new sickle cell anemia treatments.